121 related articles for article (PubMed ID: 33306617)
1. What to Expect From the New ASCO/CAP Guideline Recommendations for Hormone Receptor Testing in Breast Cancer: A National Reference Laboratory Experience.
Mahlow J; Goold EA; Jedrzkiewicz J; Gulbahce HE
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):245-250. PubMed ID: 33306617
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC
J Clin Oncol; 2020 Apr; 38(12):1346-1366. PubMed ID: 31928404
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC
Arch Pathol Lab Med; 2020 May; 144(5):545-563. PubMed ID: 31928354
[TBL] [Abstract][Full Text] [Related]
4. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B; Kane JL; Valente AL; van Laar R; Gallagher C; Shriver CD; Ellsworth RE
Ann Surg Oncol; 2013 Jan; 20(1):87-93. PubMed ID: 22875649
[TBL] [Abstract][Full Text] [Related]
5. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
6. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
7. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
[TBL] [Abstract][Full Text] [Related]
8. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data.
Troxell ML; Long T; Hornick JL; Ambaye AB; Jensen KC
Arch Pathol Lab Med; 2017 Oct; 141(10):1402-1412. PubMed ID: 28714765
[TBL] [Abstract][Full Text] [Related]
10. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
11. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
12. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
Qian XL; Wen HY; Yang YL; Gu F; Guo XJ; Liu FF; Zhang L; Zhang XM; Fu L
Breast Cancer Res Treat; 2016 Aug; 159(1):31-9. PubMed ID: 27455837
[TBL] [Abstract][Full Text] [Related]
13. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
[TBL] [Abstract][Full Text] [Related]
14. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
[TBL] [Abstract][Full Text] [Related]
15. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
16. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
Gulbahce HE
Am J Clin Pathol; 2017 Oct; 148(4):308-313. PubMed ID: 28967951
[TBL] [Abstract][Full Text] [Related]
17. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
[TBL] [Abstract][Full Text] [Related]
18. High Fidelity of Breast Biomarker Metrics: A 10-Year Experience in a Single, Large Academic Institution.
Zhang H; Han M; Varma KR; Clark BZ; Bhargava R; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2018; 26(10):697-700. PubMed ID: 30095467
[TBL] [Abstract][Full Text] [Related]
19. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
20. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
